相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Class I Hdac Inhibitor Mgcd0103 Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Initiating Cells by Upregulating Dickkopf-1 and Non-Canonical Wnt Signaling
Oncotarget (2015)
Resveratrol- sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells
Catherine Andreadi et al.
AUTOPHAGY (2014)
Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives
Chiharu Sakane et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells
Selvaraju Karthik et al.
BIOMEDICINE & PHARMACOTHERAPY (2014)
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Aristeidis Chaidos et al.
BLOOD (2014)
shRNA screening identifies JMJD1C as being required for leukemia maintenance
Patrycja Sroczynska et al.
BLOOD (2014)
The promise and failures of epigenetic therapies for cancer treatment
Pasano Bojang et al.
CANCER TREATMENT REVIEWS (2014)
Anti-Tumoral Effect of the Non-Nucleoside DNMT Inhibitor RG108 in Human Prostate Cancer Cells
Ines Graca et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Cytostatic and Apoptotic Effects of DNMT and HDAC Inhibitors in Endometrial Cancer Cells
Shaohua Xu et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia
M. A. Dawson et al.
LEUKEMIA (2014)
Epigenetics and Oncology
Padmaja Mummaneni et al.
PHARMACOTHERAPY (2014)
Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a
Ramzi F. Sweis et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Scott R. Daigle et al.
BLOOD (2013)
Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells
Hilary M. Collins et al.
BMC CANCER (2013)
Anticancer efficacy of cisplatin and trichostatin A 5-aza-2′-deoxycytidine on ovarian cancer
F. Meng et al.
BRITISH JOURNAL OF CANCER (2013)
Highly Ligand Efficient and Selective N-2(Thioethyl)picolinamide Histone Deacetylase Inhibitors Inspired by the Natural Product Psammaplin A
Matthias G. J. Baud et al.
CHEMMEDCHEM (2013)
Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
Yasuhiro Oki et al.
CLINICAL CANCER RESEARCH (2013)
Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers
Laleh Amiri-Kordestani et al.
CLINICAL CANCER RESEARCH (2013)
Rejuvenating Sirtuins: The Rise of a New Family of Cancer Drug Targets
Santina Bruzzone et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains
Olivier Mirguet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP
Feng Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Chromatin proteins and modifications as drug targets
Kristian Helin et al.
NATURE (2013)
Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases
Fanny L. Cherblanc et al.
NATURE CHEMICAL BIOLOGY (2013)
Histone lysine demethylases as targets for anticancer therapy
Jonas W. Hojfeldt et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
DNA Methyltransferase Inhibitor Zebularine Inhibits Human Hepatic Carcinoma Cells Proliferation and Induces Apoptosis
Kazuaki Nakamura et al.
PLOS ONE (2013)
Resveratrol Inhibits the Growth of Gastric Cancer by Inducing G1 Phase Arrest and Senescence in a Sirt1-Dependent Manner
Qing Yang et al.
PLOS ONE (2013)
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Sarah K. Knutson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model
Deepali Kurundkar et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2013)
5-hydroxymethylcytosine and its potential roles in development and cancer
Gerd P. Pfeifer et al.
EPIGENETICS & CHROMATIN (2013)
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
Hanne Fredly et al.
CLINICAL EPIGENETICS (2013)
The class I-specific HDAC inhibitor MS-275 modulates the differentiation potential of mouse embryonic stem cells
Gianluigi Franci et al.
BIOLOGY OPEN (2013)
The journey of resveratrol from yeast to human
Silvie Timmers et al.
AGING-US (2012)
Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management
Guillermo Garcia-Manero
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Sensitization of tumor cells by targeting histone deacetylases
Paola Perego et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Sirtuin activators and inhibitors
Jose M. Villalba et al.
BIOFACTORS (2012)
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
R. Pili et al.
BRITISH JOURNAL OF CANCER (2012)
The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells
William J. Harris et al.
CANCER CELL (2012)
MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma
Robert J. Amato et al.
CANCER INVESTIGATION (2012)
DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling
Jurate Savickiene et al.
CELL BIOLOGY INTERNATIONAL (2012)
Design, Synthesis, and Biological Evaluation of 2-Aminobenzanilide Derivatives as Potent and Selective HDAC Inhibitors
Diana A. Stolfa et al.
CHEMMEDCHEM (2012)
Discovery of curcumin, a component of golden spice, and its miraculous biological activities
Subash C. Gupta et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2012)
Molecular Pathways: The Complexity of the Epigenome in Cancer and Recent Clinical Advances
Mariarosaria Conte et al.
CLINICAL CANCER RESEARCH (2012)
Decitabine for acute myeloid leukemia
Peter W. Marks
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Resveratrol in cardiovascular disease: what is known from current research?
Hong Wang et al.
HEART FAILURE REVIEWS (2012)
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Omar Khan et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
Garcinol, a Histone Acetyltransferase Inhibitor, Radiosensitizes Cancer Cells by Inhibiting Non-Homologous End Joining
Takahiro Oike et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Histone Deacetylase Inhibitors: Structure-Based Modeling and Isoform-Selectivity Prediction
Laura Silvestri et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2012)
DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
Min Chen et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Trials with 'epigenetic' drugs: An update
Angela Nebbioso et al.
MOLECULAR ONCOLOGY (2012)
LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism
Roberto Rosato et al.
LEUKEMIA RESEARCH (2012)
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
Laurens Kruidenier et al.
NATURE (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
Dnmt3a is essential for hematopoietic stem cell differentiation
Grant A. Challen et al.
NATURE GENETICS (2012)
Targeting Epigenetic Readers in Cancer
Mark A. Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Characterisation of a Tip60 Specific Inhibitor, NU9056, in Prostate Cancer
Kelly Coffey et al.
PLOS ONE (2012)
Chemosensitization of tumors by resveratrol
Subash C. Gupta et al.
RESVERATROL AND HEALTH (2011)
Resveratrol and cellular mechanisms of cancer prevention
Yogeshwer Shukla et al.
RESVERATROL AND HEALTH (2011)
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Scott R. Daigle et al.
CANCER CELL (2011)
Combination Therapy with Vidaza and Entinostat Suppresses Tumor Growth and Reprograms the Epigenome in an Orthotopic Lung Cancer Model
Steven A. Belinsky et al.
CANCER RESEARCH (2011)
Nicotinamide Blocks Proliferation and Induces Apoptosis of Chronic Lymphocytic Leukemia Cells through Activation of the p53/miR-34a/SIRT1 Tumor Suppressor Network
Valentina Audrito et al.
CANCER RESEARCH (2011)
5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers but Its Levels Do Not Correlate with IDH1 Mutations
Seung-Gi Jin et al.
CANCER RESEARCH (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
Epigenetic aberrations during oncogenesis
Maria Hatziapostolou et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
Angela Nebbioso et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
M. J. Walter et al.
LEUKEMIA (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss
Christopher J. Klein et al.
NATURE GENETICS (2011)
Cancer epigenetics reaches mainstream oncology
Manuel Rodriguez-Paredes et al.
NATURE MEDICINE (2011)
Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells
Michele Cea et al.
PLOS ONE (2011)
Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors
Ju-Hee Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine
Shinsuke Ito et al.
SCIENCE (2011)
Failure of Hypomethylating Agent-Based Therapy in Myelodysplastic Syndromes
Tapan M. Kadia et al.
SEMINARS IN ONCOLOGY (2011)
Potential beneficial effects of butyrate in intestinal and extrainitestinal diseases
Roberto Berni Canani et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Sirtuins inhibitors: The approach to affinity and selectivity
Yana Cen
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule Inhibitor
Erin M. Bowers et al.
CHEMISTRY & BIOLOGY (2010)
Solving the Dnmt2 enigma
Matthias Schaefer et al.
CHROMOSOMA (2010)
Structural studies on human 2-oxoglutarate dependent oxygenases
Michael A. McDonough et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2010)
RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage
Matthias Schaefer et al.
GENES & DEVELOPMENT (2010)
SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1
Michelle Pacholec et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-Diamino-7-aminoalkoxy-quinazolines.
Feng Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation
Giovanni L. Gravina et al.
MOLECULAR CANCER (2010)
The Histone Deacetylase Inhibitor MGCD0103 Has Both Deacetylase and Microtubule Inhibitory Activity
KeeMing Chia et al.
MOLECULAR PHARMACOLOGY (2010)
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Gillian L. Dalgliesh et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
DNMT3A Mutations in Acute Myeloid Leukemia.
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
J-H. Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto- and DNA-protective dietary compounds
Kavita Bisht et al.
TOXICOLOGY (2010)
Chemical mechanisms of histone lysine and arginine modifications
Brian C. Smith et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2009)
The Emerging Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors
Astrid Spannhoff et al.
CHEMMEDCHEM (2009)
SIRT1 controls circadian clock circuitry and promotes cell survival: a connection with age-related neoplasms
Brittney Jung-Hynes et al.
FASEB JOURNAL (2009)
Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead
Antonello Mai et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Discovery of a 2,4-Diamino-7-aminoalkoxyquinazoline as a Potent and Selective Inhibitor of Histone Lysine Methyltransferase G9a
Feng Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Identification of Cell-Active Lysine Specific Demethylase 1-Selective Inhibitors
Rie Ueda et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Recent progress in the biology and physiology of sirtuins
Toren Finkel et al.
NATURE (2009)
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
Gijs van Haaften et al.
NATURE GENETICS (2009)
Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294
Yanqi Chang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2009)
Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice
Gyeong-Min Do et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia
Rebecca B. Klisovic et al.
CLINICAL CANCER RESEARCH (2008)
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
Leigh Ellis et al.
CLINICAL CANCER RESEARCH (2008)
Resveratrol: A natural compound with pharmacological potential in neurodegenerative diseases
Hector I. Rocha-Gonzalez et al.
CNS NEUROSCIENCE & THERAPEUTICS (2008)
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer
Cesare Gridelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Suramin: Clinical Uses and Structure-Activity Relationships
Ross P. McGeary et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2008)
A new path to the cancer epigenome
Victoria M. Richon
NATURE BIOTECHNOLOGY (2008)
Molecular origins of cancer: Epigenetics in cancer
Manel Esteller
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Multivalent engagement of chromatin modifications by linked binding modules
Alexander J. Ruthenburg et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Jill C. Milne et al.
NATURE (2007)
New nomenclature for chromatin-modifying enzymes
C. David Allis et al.
CELL (2007)
How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers
Sean D. Taverna et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails
Hongda Huang et al.
BMC STRUCTURAL BIOLOGY (2007)
Vorinostat in cutaneous T-CELL lymphoma
Madeleine Duvic et al.
DRUGS OF TODAY (2007)
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
M. Candelaria et al.
ANNALS OF ONCOLOGY (2007)
Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease
Tiago Fleming Outeiro et al.
SCIENCE (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The therapeutic uses of chromatin-modifying agents
Antonello Mai
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Activation of p300 histone acetyltransferase by small molecules altering enzyme structure: Probed by surface-enhanced Raman spectroscopy
K. Mantelingu et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2007)
Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Jing Tan et al.
GENES & DEVELOPMENT (2007)
Small molecule inhibitors of histone arginine methyltransferases: Homology modeling, molecular docking, binding mode analysis, and biological evaluations
Rino Ragno et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress
Crescent R. Isham et al.
BLOOD (2007)
Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin
Anja Schuetz et al.
STRUCTURE (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
Stefan Kubicek et al.
MOLECULAR CELL (2007)
Cancer epigenomics: DNA methylomes and histone-modification maps
Manel Esteller
NATURE REVIEWS GENETICS (2007)
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α
David Z. Qian et al.
CANCER RESEARCH (2006)
Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases
Johnathan R. Whetstine et al.
CELL (2006)
Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes
B Heltweg et al.
CANCER RESEARCH (2006)
Curcumin is an Inhibitor of p300 Histone Acetylatransferase
Monica G. Marcu et al.
MEDICINAL CHEMISTRY (2006)
The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma
M Herranz et al.
BLOOD (2006)
De novo CpG island methylation in human cancer cells
KW Jair et al.
CANCER RESEARCH (2006)
Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1
AD Napper et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Procainamide is a specific inhibitor of DNA methyltransferase 1
BH Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A decade of histone acetylation: Marking eukaryotic chromosomes with specific codes
A Kimura et al.
JOURNAL OF BIOCHEMISTRY (2005)
Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity
L Stimson et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids
WJ Lee et al.
MOLECULAR PHARMACOLOGY (2005)
Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases
B Brueckner et al.
CANCER RESEARCH (2005)
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
QC Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process
F Forneris et al.
FEBS LETTERS (2005)
Simultaneous detection of six stone fruit viruses by non-isotopic molecular hybridization using a unique riboprobe or 'polyprobe'
MC Herranz et al.
JOURNAL OF VIROLOGICAL METHODS (2005)
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George et al.
BLOOD (2005)
Low-dose suramin enhanced paclitaxel activity in chemotherapy-Naive and paclitaxel-pretreated human breast xenograft tumors
SH Song et al.
CLINICAL CANCER RESEARCH (2004)
Generation of hydrogen peroxide primarily contributes to the induction of Fe(II)-dependent apoptosis in Jurkat cells by (-)-epigallocatechin gallate
H Nakagawa et al.
CARCINOGENESIS (2004)
Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription
K Balasubramanyam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors
V Sagar et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5
M Biel et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2004)
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor
A Vannini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Identification of selective inhibitors of NAD+-dependent deacetylases using phenotypic screens in yeast
M Hirao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Reduced expression of oestrogen receptor β in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model
GP Skliris et al.
JOURNAL OF PATHOLOGY (2003)
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
KT Howitz et al.
NATURE (2003)
Small molecule modulators of histone acetyltransferase p300
K Balasubramanyam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Psammaplins from the sponge Pseudoceratina purpurea:: Inhibition of both histone deacetylase and DNA methyltransferase
IC Piña et al.
JOURNAL OF ORGANIC CHEMISTRY (2003)
A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly
DJ Stewart et al.
ANNALS OF ONCOLOGY (2003)
Inhibition of DNA methylation and reactivation of silenced genes by zebularine
JC Cheng et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks
AJ David et al.
INVESTIGATIONAL NEW DRUGS (2003)
An essential role for DNA methyltransferase DNMT3B in cancer cell survival
N Beaulieu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer
H Suzuki et al.
NATURE GENETICS (2002)
DNA methyltransferase inhibitors - state of the art
J Goffin et al.
ANNALS OF ONCOLOGY (2002)
Identification of a small molecule inhibitor of Sir2p
A Bedalov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
M Göttlicher et al.
EMBO JOURNAL (2001)
Histone deacetylase inhibitors as new cancer drugs
PA Marks et al.
CURRENT OPINION IN ONCOLOGY (2001)
Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells
Y Terao et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
DNA methylation, methyltransferases, and cancer
KD Robertson
ONCOGENE (2001)
Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
AJ Bannister et al.
NATURE (2001)
HATs off: Selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF
OD Lau et al.
MOLECULAR CELL (2000)
分享论文
